Steven Fishbane

Summary

Affiliation: Winthrop-University Hospital
Country: USA

Publications

  1. ncbi Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets
    Steven Fishbane
    Division of Nephrology, Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
    Clin J Am Soc Nephrol 2:1274-82. 2007
  2. pmc Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results
    Steven Fishbane
    Winthrop University Hospital, Department of Nephrology, Mineola, New York 11501, USA
    Clin J Am Soc Nephrol 3:1718-25. 2008
  3. doi Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York, USA
    Kidney Int 77:175-7. 2010
  4. ncbi Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York, USA
    Kidney Int 68:1337-43. 2005
  5. doi Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Am J Kidney Dis 54:647-52. 2009
  6. pmc Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY 11501, USA
    Clin J Am Soc Nephrol 4:57-61. 2009
  7. ncbi Iron supplementation in renal anemia
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Semin Nephrol 26:319-24. 2006
  8. ncbi Iron management in nondialysis-dependent CKD
    Steven Fishbane
    SUNY at Stony Brook School of Medicine, USA
    Am J Kidney Dis 49:736-43. 2007
  9. ncbi The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?
    S Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 72:806-13. 2007
  10. ncbi Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells
    Steven Fishbane
    Winthrop University Hospital, Division of Nephrology, Nephrology Laboratory, Mineola, New York 11501, USA
    Kidney Int 65:452-8. 2004

Detail Information

Publications75

  1. ncbi Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets
    Steven Fishbane
    Division of Nephrology, Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
    Clin J Am Soc Nephrol 2:1274-82. 2007
    ....
  2. pmc Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results
    Steven Fishbane
    Winthrop University Hospital, Department of Nephrology, Mineola, New York 11501, USA
    Clin J Am Soc Nephrol 3:1718-25. 2008
    ..ACHIEVE included a 6-week screening phase, including vitamin D washout, a 16-week dose-titration phase, and an 11-week assessment phase...
  3. doi Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York, USA
    Kidney Int 77:175-7. 2010
    ..We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure...
  4. ncbi Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York, USA
    Kidney Int 68:1337-43. 2005
    ..Therapy, however, is often observed to be associated with recurrent cyclic fluctuations in hemoglobin levels. The purpose of this analysis was to describe the phenomenology of hemoglobin cycling during rHuEPO treatment...
  5. doi Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Am J Kidney Dis 54:647-52. 2009
    ..Because of this, it could be helpful in treating patients with proteinuric renal diseases. The objective is to determine the effect of oral paricalcitol on protein excretion in patients with proteinuric chronic kidney disease...
  6. pmc Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY 11501, USA
    Clin J Am Soc Nephrol 4:57-61. 2009
    ..One contributing factor is iron deficiency, which may be particularly problematic during erythropoietin replacement therapy. The aim of this study was to examine the prevalence of iron deficiency in nondialysis CKD...
  7. ncbi Iron supplementation in renal anemia
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Semin Nephrol 26:319-24. 2006
    ..This review discusses the physiology of iron balance, derangements in iron balance in chronic kidney disease (CKD), and the diagnosis and treatment of iron deficiency in patients treated with rHuEPO...
  8. ncbi Iron management in nondialysis-dependent CKD
    Steven Fishbane
    SUNY at Stony Brook School of Medicine, USA
    Am J Kidney Dis 49:736-43. 2007
    ....
  9. ncbi The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?
    S Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 72:806-13. 2007
    ..In this review, we consider the recent literature, the change in FDA warnings, and new National Kidney Foundation Anemia Guidelines. Suggestions for new Hb targets during erythropoiesis-stimulating agent treatment are presented...
  10. ncbi Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells
    Steven Fishbane
    Winthrop University Hospital, Division of Nephrology, Nephrology Laboratory, Mineola, New York 11501, USA
    Kidney Int 65:452-8. 2004
    ..Erythropoietin has recently been found to have cytoprotective effects in the central nervous system (CNS) and retina. The purpose of this study was to determine if darbepoetin alfa (DA) has cytoprotective properties in renal tissues...
  11. doi Anemia and cardiovascular risk in the patient with kidney disease
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Heart Fail Clin 4:401-10. 2008
    ..To date, however, results from interventional studies have been disappointing in this regard. This article reviews the relationship between anemia in CKD and cardiovascular risk and explores current knowledge on ESA treatment...
  12. ncbi Anemia treatment in chronic renal insufficiency
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY 11501, USA
    Semin Nephrol 22:474-8. 2002
    ..In this review, the benefits of anemia therapy are weighed against the risks and costs. On balance, it is concluded that anemia treatment meets a basic and important health need in these patients...
  13. ncbi Longitudinal predictors of uremic pruritus
    Shayan Shirazian
    Winthrop University Hospital, Division of Nephrology, Mineola, New York
    J Ren Nutr 23:428-31. 2013
    ..The primary purpose of this study was to analyze the relationship between pruritus and common tests of bone and mineral disease...
  14. ncbi How can erythropoietin requirements be reduced in dialysis patients?
    Peter Kotanko
    Renal Research Institute, New York, New York 10128, USA
    Semin Dial 19:363-72. 2006
  15. doi Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment
    Alan S Kliger
    Department of Medicine, Hospital of St Raphael, Yale School of Medicine, New Haven, CT 06511, USA
    Clin J Am Soc Nephrol 7:354-7. 2012
    ..Patients, along with their physicians, can examine Hb level in the context of patients' perception of their quality of life and use ESAs judiciously to improve these perceptions...
  16. ncbi What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease
    Steven Fishbane
    Winthrop University Hospital, 200 Old Country Road, Mineola, NY 11501, USA
    Blood Purif 25:53-7. 2007
    ..In addition, causes for diminished response and refractory anemia must be adequately evaluated. In this article, factors important for achieving Hb 11-13 g/dl in patients with ESRD are reviewed...
  17. ncbi Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)
    Nathan W Levin
    Renal Research Institute, New York, NY 10128, USA
    Lancet 370:1415-21. 2007
    ..We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients...
  18. ncbi Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure
    Harini Chittineni
    Winthrop University Hospital, Mineola, NY, USA
    Am J Nephrol 27:55-62. 2007
    ..The purpose of this study was to describe the incidence of ARF, to ascertain risk factors for its development, and to determine whether ARF impacts hospital outcomes...
  19. doi Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective
    Steven Fishbane
    Department of Nephrology, Winthrop University Hospital, Mineola, NY 11501, USA
    Kidney Int 75:358-65. 2009
    ..We do not seek to propose that treatment with ESAs to higher Hgb targets is safe, but rather to use this outlier experience to gain knowledge and to generate hypotheses to be tested in future studies...
  20. ncbi Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY 11501, USA
    J Clin Pharmacol 47:1390-7. 2007
    ..The long half-life may permit effective anemia management with extended dosing intervals. Phase III clinical studies support the role of C.E.R.A. in managing anemia in patients with chronic kidney disease...
  21. ncbi Safety in iron management
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY 11501, USA
    Am J Kidney Dis 41:18-26. 2003
    ..This article reviews safety data surrounding the IV iron therapies...
  22. ncbi The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York, USA
    Arch Intern Med 167:1664-9. 2007
    ..The purpose of this study was to test whether the addition of intensive clinical case management to clinical guidelines could lead to a reduction in LOS that was not achievable by guidelines alone, while maintaining quality of care...
  23. pmc More on renal salt wasting without cerebral disease: response to saline infusion
    Solomon Bitew
    Division of Nephrology and Hypertension and Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
    Clin J Am Soc Nephrol 4:309-15. 2009
    ..This controversy stems from overlapping clinical and laboratory findings and an inability to assess the volume status of these patients. The authors report another case of RSW without clinical cerebral disease and contrast it to SIADH...
  24. doi Anemia in chronic kidney disease: status of new therapies
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York, USA
    Curr Opin Nephrol Hypertens 18:112-5. 2009
    ..In addition, new drugs are being developed in both the ESA and intravenous (i.v.) iron classes...
  25. ncbi Stabilizing hemoglobin levels: what's new in IV iron and anemia management?
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Nephrol Nurs J 35:493-502. 2008
    ..This article will help nephrology nurses better understand the balance between intravenous iron and erythropoiesis-stimulating agents to stabilize Hib levels...
  26. doi Hypothesis: an erythropoietin honeymoon phase exists
    Steven Fishbane
    Department of Medicine, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 78:646-9. 2010
    ..We propose investigation of this phenomenon as it could lead to less expensive and safer approaches to treatment of CKD anemia...
  27. ncbi The role of erythropoiesis-stimulating agents in the treatment of anemia
    Steven Fishbane
    Winthrop Nephrology Associates, 200 Old Country Rd, Suite 135, Mineola, NY 11501, USA
    Am J Manag Care 16:S67-73. 2010
    ..With the multiple safety issues involved in administering ESAs, our institution prefers to err on the side of caution until these concerns are resolved...
  28. ncbi Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia
    John K Maesaka
    Department of Medicine, Division of Nephrology and Hypertension, Winthrop University Hospital, Mineola, NY 11501, USA
    Semin Nephrol 22:407-14. 2002
    ....
  29. doi The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial
    Shayan Shirazian
    Division of Nephrology, Winthrop University Hospital, Mineola, New York, USA
    J Ren Nutr 23:308-14. 2013
    ..Because of this, we studied whether vitamin D2 treatment with ergocalciferol is effective for relief of uremic pruritus severity as measured by pruritus severity surveys...
  30. ncbi N-acetylcysteine in the prevention of contrast-induced nephropathy
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York 11501, USA
    Clin J Am Soc Nephrol 3:281-7. 2008
    ..Contrast-induced nephropathy (CIN) is a common clinical problem that is growing in importance as an increasing number of tests and procedures that utilize contrast media are performed...
  31. doi A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis
    Steven Fishbane
    Winthrop University Hospital, Division of Nephrology and Hypertension, Mineola, NY 11501, USA
    Am J Kidney Dis 55:307-15. 2010
    ..Sevelamer carbonate powder for oral suspension is a new dosage form of sevelamer, which may be suited to once-daily dosing...
  32. ncbi Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters
    Jesse Goldman
    Temple University, Philadelphia, PA, USA
    Clin Nephrol 77:55-61. 2012
    ..We evaluated the efficacy and safety of the thrombolytic agent tenecteplase for the treatment of dysfunctional hemodialysis (HD) catheters...
  33. ncbi N-acetylcysteine in the prevention of radiocontrast-induced nephropathy
    Steven Fishbane
    Winthrop University Hospital, Mineola, New York 11501, USA
    J Am Soc Nephrol 15:251-60. 2004
    ..The following will review the individual studies, attempt to reconcile the divergent results, and propose future research needs...
  34. doi Forty-eight hour kidney transplant admissions
    ERIC SISKIND
    Department of Transplantation, North Shore Long Island Jewish Health System, Manhasset, NY, USA
    Clin Transplant 27:E431-4. 2013
    ..We did not encounter any readmissions within the first seven post-operative days. Further improvements in clinical management will enhance the potential to shorten the length of hospital stay for all kidney transplant recipients. ..
  35. ncbi The effect of hemodialysis ultrafiltration on changes in whole blood viscosity
    Shayan Shirazian
    Division of Nephrology, Winthrop University Hospital, Mineola, New York, USA
    Hemodial Int 16:342-50. 2012
    ..63, P < 0.01). We found that hemodialysis UF causes a surge in WBV. The surge was of greater magnitude in high than in low UF patients...
  36. ncbi Implications of neocytolysis for optimal management of anaemia in chronic kidney disease
    Clarence P Alfrey
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Nephron Clin Pract 106:c149-56. 2007
    ..Understanding neocytolysis and its relationship to fluctuating serum erythropoietin levels might help to better understand optimal treatment with erythropoietic agents...
  37. doi Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  38. doi A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    Marc A Pfeffer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2019-32. 2009
    ..Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested...
  39. doi Changes to the end-stage renal disease quality incentive program
    Steven Fishbane
    North Shore LIJ Health System, Department of Medicine, Division of Nephrology, Hofstra North Shore LIJ School of Medicine, Great Neck, NY 11021, USA
    Kidney Int 81:1167-71. 2012
    ..In this article, we describe the program structure, quality measures, scoring system, and financial impact...
  40. ncbi The QIP: will it improve dialysis care? An overview
    Steven Fishbane
    North Shore LIJ Health System, Great Neck, NY, USA
    Nephrol News Issues 26:20, 22-4, 26. 2012
    ..In this review we discuss the QIP, with a comprehensive explanation of measures and scoring procedure...
  41. ncbi Hyponatremia in community-acquired pneumonia
    Vinay Nair
    Division of Nephrology, Winthrop University Hospital, Mineola, NY, USA
    Am J Nephrol 27:184-90. 2007
    ..The purpose of this study was to describe the incidence of hyponatremia in CAP and to analyze risk factors for its occurrence...
  42. ncbi A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography
    John D Durham
    Division of Nephrology, Department of Pharmacy, and Division of Cardiology, Winthrop University Hospital, Mineola, New York, USA
    Kidney Int 62:2202-7. 2002
    ..The purpose of the current study was to evaluate the efficacy of NAC for the prevention of CN in the setting of cardiac angiography...
  43. ncbi Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients
    M V DeVita
    Division of Nephrology, Department of Medicine, Lenox Hill Hospital, New York, NY, USA
    Clin Nephrol 60:335-40. 2003
    ....
  44. pmc Update on membranoproliferative GN
    Naveed Masani
    Division of Nephrology, Winthrop University Hospital, Mineola, New York, Division of Kidney Diseases and Hypertension, Hofstra North Shore Long Island Jewish School of Medicine, Great Neck, New York
    Clin J Am Soc Nephrol 9:600-8. 2014
    ..Evaluation and treatment of this complex disorder rest on defining the underlying mechanisms. ..
  45. doi Meeting the 2012 QIP (Quality Incentive Program) clinical measures: strategies for dialysis centers
    Steven Fishbane
    North Shore LIJ Health System, Department of Medicine, Division of Nephrology, Hofstra North Shore LIJ School of Medicine, Great Neck, NY, USA
    Am J Kidney Dis 60:S5-13; quiz S14-7. 2012
    ..Strategies and solutions that address provider- and patient-related factors also are discussed to help ensure that more dialysis centers meet the new QIP clinical measures for performance year 2012/payment year 2014...
  46. ncbi A physician's perseverance uncovers problems in a key nephrology study
    Steven Fishbane
    Hofstra North Shore LIJ School of Medicine, Great Neck, New York, USA
    Kidney Int 82:135-7. 2012
    ..Coyne shows that the published results did not completely and clearly represent the study's actual results. We discuss the implications and make recommendations to prevent such occurrences...
  47. ncbi Posttransplant anemia: the role of sirolimus
    Steven Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 76:376-82. 2009
    ..Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management...
  48. doi Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4
    Steven Fishbane
    Division of Nephrology, Winthrop University Hospital, 200 Old Country Rd, 135, Mineola, NY 11501, USA
    J Thromb Thrombolysis 31:99-106. 2011
    ..Tenecteplase administered as a 1 h or 1 h plus extended dwell was associated with improved HD catheter function in the TROPICS 4 trial...
  49. ncbi Refractory anemia in a patient with allergy to intravenous iron drugs
    S Fishbane
    Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 69:1910-3. 2006
  50. ncbi A randomized trial of iron deficiency testing strategies in hemodialysis patients
    S Fishbane
    Winthrop University Hospital, Mineola, and Brookdale Medical Center, Brooklyn, New York, USA
    Kidney Int 60:2406-11. 2001
    ..The purpose of this study was to compare iron management guided by serum ferritin and transferrin saturation to management guided by CHr...
  51. ncbi Self-assessed quality of life in peritoneal dialysis patients
    S K Mittal
    Division of Nephrology and Hypertension, Winthrop University Hospital, Mineola, NY, USA
    Am J Nephrol 21:215-20. 2001
    ..We sought to evaluate these indices in PD patients: (1) as measures of QOL, (2) predictors of QOL, (3) to study change in QOL over time, and (4) to compare QOL in PD vs. hemodialysis patients...
  52. ncbi Self-assessed physical and mental function of haemodialysis patients
    S K Mittal
    Winthrop-University Hospital, Mineola, New York, USA
    Nephrol Dial Transplant 16:1387-94. 2001
    ..CONCLUSIONS: Self assessed physical and mental health of haemodialysis patients is markedly diminished compared to the general population and other chronic diseases...
  53. ncbi Iron treatment: impact of safety issues
    S Fishbane
    Dialysis Services, Winthrop University Hospital, Mineola, NY 11501, USA
    Am J Kidney Dis 32:S152-6. 1998
    ..A recommendation is made, in contrast to the NKF-DOQI Guidelines, that i.v. iron should not be administered to hemodialysis patients if the serum ferritin level if greater than 500 ng/mL...
  54. ncbi Review of issues relating to iron and infection
    S Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, NY, USA
    Am J Kidney Dis 34:S47-52. 1999
    ..There is no reason to alter current iron treatment strategies based on this literature...
  55. ncbi Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran
    Beckie Michael
    Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Kidney Int 61:1830-9. 2002
    ..S. under FDA's priority drug review. This Phase IV study was designed to evaluate the safety of a single dose of intravenous SFGC as compared to placebo and a historical iron dextran control...
  56. ncbi Hemoglobin variability in epoetin-treated hemodialysis patients
    Jeffrey S Berns
    Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Kidney Int 64:1514-21. 2003
    ..This study examines hemoglobin variability under conditions of standard clinical practice in epoetin-treated hemodialysis patients...
  57. ncbi Hepatic iron in hemodialysis patients
    Steven Fishbane
    Kidney Int 66:1714-5. 2004
  58. ncbi Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment
    Steven Fishbane
    Semin Dial 17:336-41. 2004
    ..Clinical judgment is critical to properly weigh the risks and benefits of intravenous iron treatment in the context of the individual patient...
  59. doi Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines
    Steven Fishbane
    Semin Dial 21:217-20. 2008
    ..Instead, clinical judgment is critical to properly weigh risks and benefits of i.v. iron treatment, and to determine whether iron treatment is appropriate for a given patient with higher levels of iron tests...
  60. doi The optimal hemoglobin in dialysis patients- a critical review
    Ajay K Singh
    Semin Dial 21:1-6. 2008
    ..We also suggest that the current reimbursement system for erythropoiesis stimulating agent treatment potentially encourages unsafe overtreatment...
  61. pmc History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients
    Steven M Brunelli
    Renal, Electrolyte and Hypertension Division of the Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin J Am Soc Nephrol 3:777-82. 2008
    ..The causal nature of this association has been difficult to ascertain because of potential time-dependent confounding, for which traditional statistical methods do not control...
  62. pmc Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
    ..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
  63. ncbi Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Department o f Medicine, Henry Ford Hospital, Detroit, Michigan, USA
    Clin Ther 29:626-39. 2007
    ..A continuous erythropoietin receptor activator (C.E.R.A.) is currently in development for the treatment of anemia in patients with chronic renal disease (CRD) receiving or not receiving dialysis treatment...
  64. ncbi Evidence and implications of haemoglobin cycling in anaemia management
    Steven Fishbane
    Nephrol Dial Transplant 22:2129-32. 2007
  65. ncbi Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex
    Beckie Michael
    Thomas Jefferson University, Philadelphia, PA 19107, USA
    Nat Clin Pract Nephrol 2:92-100. 2006
    ..This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron...
  66. ncbi The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients
    Jeffrey S Berns
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19146, USA
    Hemodial Int 9:255-63. 2005
    ..The decline in mean weekly dose of epoetin was likely a result of withholding doses out of concern among providers about risk of reimbursement denial...
  67. ncbi Recombinant human erythropoietin: has treatment reached its full potential?
    Steven Fishbane
    Semin Dial 19:1-4. 2006
    ..In this review the current state of r-HuEPO treatment is compared to the normal biology of erythropoietin and potential pitfalls caused by divergences are explored...
  68. ncbi EPO adjuvant treatments: a need for more evidence
    Steven Fishbane
    Am J Kidney Dis 47:683-5. 2006
  69. ncbi Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients
    Daniel W Coyne
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Kidney Int 63:217-24. 2003
    ....
  70. ncbi How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis?
    Kathleen L Wyne
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 8857, USA
    Semin Dial 19:8-24. 2006
  71. ncbi Hemoglobin variability and mortality in ESRD
    Wei Yang
    Center for Clinical Epidemiology and Biostatistics and the Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Soc Nephrol 18:3164-70. 2007
    ..Patient characteristics accounted for very little of the variation in our hemoglobin variability metric (R2 = 0.019). We conclude that greater hemoglobin variability is independently associated with higher mortality...
  72. pmc Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study
    Rajnish Mehrotra
    Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    Clin J Am Soc Nephrol 3:1437-45. 2008
    ..This phase IIIb trial assessed the efficacy of increased dosages (3000 to 4500 mg/d) of reformulated lanthanum carbonate (500-, 750-, and 1000-mg tablets) in nonresponders to dosages of up to 3000 mg/d...
  73. ncbi Quality outcomes and obstacles to their achievement in end-stage renal disease
    Steven Fishbane
    Semin Dial 15:30-4. 2002
    ..However, there are certain barriers to quality of care that may hinder such efforts. In this article we discuss obstacles to quality of care in ESRD and present potential solutions...
  74. ncbi Safety issues with iron sucrose
    Steven Fishbane
    Am J Kidney Dis 41:899; author reply 900. 2003
  75. ncbi Cardiovascular risk evaluation before kidney transplantation
    Steven Fishbane
    J Am Soc Nephrol 16:843-5. 2005